Project Grant R01HL177550
- The Project Grant award titled "Alveolar Epithelial Stress Signaling in Lung Fibrosis" is funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $683,564.00 over the period of Jul 1, 2025 to Mar 31, 2030. The award supports comprehensive research focused on understanding the role of aberrant alveolar epithelial cells in the pathogenesis of pulmonary fibrosis, a devastating and progressive lung disease. The research aims to investigate...
- The federal Project Grant award of $108,978.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate the mechanisms underlying the age-related decline in the regenerative capacity of alveolar type 2 (AT2) cells in the lung. The principal investigator and research team at the Harvard T.H. Chan School of Public Health will conduct studies to determine whether elevated interferon gamma (IFNG) levels and changes in resident...
- This Project Grant award, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), supports research on the role of protein S-palmitoylation in TGF-beta signaling and fibrotic lung disease at Duke University. The $165,456 grant awarded on August 15, 2025 will fund a 5-year project to investigate how S-palmitoylation of the TGF-beta receptor regulates its activity and fibrotic pathways, and the potential for targeting related...
- The National Heart Lung and Blood Institute (NHLBI), through its Cardiovascular Diseases Research program (CFDA 93.837), awarded a $172,724 project grant to The Regents of the University of California, San Francisco (UCSF) on February 28, 2025. The grant supports research to investigate the epigenetic signatures and gene regulatory networks driving the trans-differentiation of alveolar type II (AT2) cells into airway-like basal cells under homeostatic conditions and in the context of fibrotic...
- This Project Grant award for $744,880.00 was provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research to investigate how lactate produced by alveolar epithelial type II cells can shift alveolar macrophages towards an anti-inflammatory phenotype, which could enable therapeutic exploitation of this innate protective mechanism in acute lung injury and acute respiratory distress syndrome. The...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $106,391 to the University of Colorado-Denver to investigate the role of developmental dysanapsis in lung development over the lifespan in an experimental bronchopulmonary dysplasia (BPD) model. The research aims to determine whether intra-amniotic endotoxin causes persistent dysanaptic growth of the airways, distal parenchyma, and vasculature in BPD, and...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $594,583 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital of Philadelphia (CHOP) Research Institute. The grant supports research to investigate the mechanisms regulating the development, expansion, and decline of neonatal lung myofibroblasts and their role in alveologenesis. Key objectives include utilizing a novel murine model to study myofibroblast lineage, characterize...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $629,498 to The Trustees of the University of Pennsylvania (UEI GM1XX56LEP58) to conduct research aimed at deciphering the molecular mechanisms underlying pediatric interstitial lung disease (CHILD). The key objectives are to: Interrogate the anomalous development of the lung epithelium in CHILD by defining the impact of a specific SFTPC gene mutation on alveolar...
- This $607,952 Project Grant award was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837). The grant supports research at the University of Pittsburgh to investigate indole metabolites as novel danger signals that activate regulated cell death pathways in lung epithelial cells, which may contribute to the pathogenesis of acute respiratory distress syndrome (ARDS). The key research objectives include...
- The federal Project Grant award of $760,374 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is supporting research by National Jewish Health to develop predictive molecular signatures for diagnosing sarcoidosis and identifying patients at risk of disease progression. The project will integrate single nucleotide polymorphisms, gene expression, and plasma metabolomics/lipidomics data using advanced machine learning to identify potential biomarkers....
This Project Grant award for $702,103 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to systematically define the signaling pathways by which the protein SFTA2 interacts with the receptor ADGRF5 to control pulmonary surfactant homeostasis. The awardee, National Jewish Health, a non-profit research center in Colorado, will use cell-based assays and mouse genetics to test the hypothesis that SFTA2 regulates alveolar surfactant levels by binding to the extracellular domain of ADGRF5 to modulate surfactant secretion and/or uptake in alveolar type II cells. This research aims to advance the understanding of this key mechanism for regulating pulmonary surfactant, which is critical for lung function and a therapeutic target for lung diseases like acute respiratory distress syndrome and genetic surfactant disorders. The award period is from September 1, 2025 to June 30, 2029.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $702.1k | 8/22/25 |